Overview

* Iovance Biotherapeutics ( IOVA ) Q3 rev grows 13% to ~$68 mln, gross margin improves to 43%

* Adjusted loss per share for Q3 beats analyst expectations

* Company expects cash position to fund operations into Q2 2027

Outlook

* Iovance reaffirms 2025 revenue guidance of $250 to $300 mln

* Centralizing manufacturing in early 2026 to improve margins

* Potential Amtagvi approvals in UK and Australia expected in 2026

Result Drivers

* AMTAGVI DEMAND - Increasing demand for Amtagvi as community treatment centers expand and drive earlier treatment

* MARGIN IMPROVEMENT - Gross margin increased to 43% due to improved execution and cost optimization

* GLOBAL EXPANSION - Recent approval in Canada and potential approvals in other countries to drive global growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $68 mln

Revenue

Q3 EPS Beat -$0.25 -$0.26

(11

Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Iovance Biotherapeutics Inc ( IOVA ) is $7.00, about 74.1% above its November 5 closing price of $1.81

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)